Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study

NCT03540472 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT03540472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03540472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
June 10, 2018
Completion date
June 10, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pure red cell aplasia